Financials · CDNA

CareDx Inc. (CDNA) financials

For the twelve months ended Sep 30, 2026, CareDx Inc. reported $497.40M of revenue and $128.63M of net income.

Revenue, TTM
$497.40M
Revenue growth, YoY
+38.9%
Net income, TTM
$128.63M
Net income growth, YoY
+82.6%
Net margin
25.9%
EPS, diluted, TTM
$2.39
EPS growth, YoY
+86.7%
Cash
$250.48M
P/E
34.48
P/S
8.92
Market cap
$4.44B
Annual revenue$379.81M
FY2016FY2025
Annual net income-$21.35M
FY2016FY2025
Annual free cash flow-$6.04M
FY2016FY2018

CDNA revenue and earnings growth

CDNA revenueQ3 2026$139.36M

Quarter YoY
+39.3%
QoQ
+5.6%
FY YoY
+13.8%
5Y CAGR
+14.6%
10Y CAGR
+29.7%

CDNA revenue was $139.36M in fiscal Q3 2026 (ended Sep 30, 2026), up 39.3% from a year earlier and up 5.6% from the prior quarter. For the full fiscal 2025 it was $379.81M, up 13.8% from fiscal 2024. Compound annual growth was +14.6% over 5 years and +29.7% over 10 years. It rose in 9 of the last 10 fiscal years. Fiscal 2025 is the highest of the 14 fiscal years on file.

CDNA net incomeQ3 2026$19.29M

Quarter YoY
12x
QoQ
-82.6%

CDNA net income was $19.29M in fiscal Q3 2026 (ended Sep 30, 2026), up about 12-fold from a year earlier and down 82.6% from the prior quarter. For the full fiscal 2025 it was -$21.35M, compared with $52.55M in fiscal 2024.

CDNA EPSQ3 2026$0.35

Quarter YoY
12x
QoQ
-83.1%

CDNA diluted EPS was $0.35 in fiscal Q3 2026 (ended Sep 30, 2026), up about 12-fold from a year earlier and down 83.1% from the prior quarter. For the full fiscal 2025 it was -$0.40, compared with $0.93 in fiscal 2024.

CDNA free cash flowQ3 2026$11.10M

Quarter YoY
-69.2%
QoQ
-61.4%

CDNA free cash flow was $11.10M in fiscal Q3 2026 (ended Sep 30, 2026), down 69.2% from a year earlier and down 61.4% from the prior quarter. For the full fiscal 2018 it was -$6.04M, compared with -$14.49M in fiscal 2017.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue$379.81M$333.79M$280.32M$321.79M$296.40M$192.19M$127.07M$76.57M$48.32M$40.63M
Cost of revenue------$45.45M$32.99M$21.37M$10.24M
Gross profit------$81.61M$43.58M$26.95M$30.39M
Research and development$71.43M$72.51M$82.42M$90.39M$76.53M$48.94M$30.71M$14.51M$12.39M$12.38M
Selling, general and admin$107.56M$125.14M$118.84M$100.40M$74.96M$48.81M$36.54M$22.98M$20.09M$20.73M
Operating income-$30.78M$40.77M-$203.36M-$77.23M-$29.73M-$22.53M-$24.53M-$15.58M-$20.29M-$37.33M
Pre-tax income-$21.08M$52.86M-$190.14M-$76.23M-$32.09M-$19.75M-$23.95M-$48.22M-$57.27M-$41.36M
Income tax$271.0K$310.0K$141.0K$379.0K-$1.43M-$1.04M-$1.98M-$1.43M-$1.71M-$1.61M
Net income-$21.35M$52.55M-$190.28M-$76.61M-$30.66M-$18.71M-$21.97M-$46.76M-$55.47M-$39.47M
EPS, basic-$0.40$1.00-$3.54-$1.44-$0.59-$0.40-$0.52-$1.31-$2.38-$2.39
EPS, diluted-$0.40$0.93-$3.54-$1.44-$0.59-$0.40-$0.52-$1.31-$2.38-$2.39
Diluted shares53.3M56.6M53.8M53.3M52.2M46.5M42.2M35.6M23.3M16.5M

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Cash and equivalents$65.43M$115.27M$82.20M$90.44M$348.70M$134.94M$38.48M$64.81M$26.47M$17.40M
Short-term investments$111.78M$145.96M$153.22M$203.17M$0$90.03M$0---
Receivables$42.63M$64.61M$51.06M$66.31M$59.76M$34.62M$24.06M$9.76M$2.99M$2.77M
Inventory$26.70M$19.50M$19.47M$19.23M$17.19M$10.01M$6.01M$4.94M$5.53M$5.46M
Current assets$257.13M$351.83M$313.71M$387.85M$433.36M$273.10M$71.92M$81.11M$26.77M$26.67M
Goodwill$40.34M$40.34M$40.34M$37.52M$36.98M$23.86M$23.86M$12.01M$12.01M$13.84M
Total assets$413.23M$491.05M$466.83M$542.99M$566.62M$368.51M$151.74M$130.70M$83.56M$76.73M
Current liabilities$89.85M$89.37M$78.07M$75.97M$77.30M$69.22M$34.83M$19.50M$42.91M$40.83M
Short-term debt-----$0$0$0$15.72M$22.85M
Long-term debt-----$0$0$0$18.34M$1.10M
Total debt-----$0$0$0$34.06M$23.94M
Total liabilities$110.13M$112.62M$205.50M$112.08M$100.75M$90.83M$52.74M$34.77M$89.52M$56.97M
Shareholders' equity$303.10M$378.43M$261.33M$430.91M$465.88M$277.68M$99.00M$95.93M-$5.95M$19.76M

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Operating cash flow$42.03M$38.05M-$18.39M-$25.24M-$19.29M$33.43M-$2.77M-$4.01M-$14.31M-$16.52M
Capital expenditures-------$2.04M$186.0K$549.0K
Free cash flow--------$6.04M-$14.49M-$17.07M
Investing cash flow$2.16M-$483.0K$40.45M-$228.50M$47.71M-$100.39M-$22.58M-$7.93M-$6.11M-$21.12M
Financing cash flow-$93.39M-$5.61M-$29.61M-$4.54M$185.64M$163.15M-$132.0K$50.27M$29.38M$24.93M
Share repurchases$87.77M$522.0K$27.54M$642.0K$0$0----
Stock-based compensation$34.86M$66.41M$49.09M$46.55M$36.08M$23.40M$22.42M$7.14M$1.74M$2.00M
Depreciation and amortization$15.02M$14.19M$14.39M$11.60M$8.80M$7.01M$5.52M$4.21M$3.73M$2.92M

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue growth, YoY13.8%19.1%-12.9%8.6%54.2%51.3%66.0%58.4%18.9%44.4%
Gross margin------64.2%56.9%55.8%74.8%
Operating margin-8.1%12.2%-72.5%-24.0%-10.0%-11.7%-19.3%-20.3%-42.0%-91.9%
Net margin-5.6%15.7%-67.9%-23.8%-10.3%-9.7%-17.3%-61.1%-114.8%-97.1%
Free cash flow margin--------7.9%-30.0%-42.0%
Return on equity-7.0%13.9%-72.8%-17.8%-6.6%-6.7%-22.2%-48.7%--199.7%
Return on assets-5.2%10.7%-40.8%-14.1%-5.4%-5.1%-14.5%-35.8%-66.4%-51.4%
Current ratio2.863.944.025.105.613.952.074.160.620.65
Debt to equity-----0.000.000.00-1.21

Source: XBRL data CareDx Inc. files with the SEC, latest filing dated Oct 29, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

CDNA peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
CDNA$497.40M+38.9%$128.63M25.9%$4.44B
UNH$449.66B+3.3%$15.88B3.5%$356.28B
ELV$201.83B+3.6%$5.13B2.5%$90.37B
CI$286.32B+6.8%$5.99B2.1%$77.89B
HUM$154.19B+22.0%$1.25B0.8%$50.82B
NTRA$2.91B+37.4%-$164.71M-5.7%$46.46B
CNC$203.90B+9.7%$1.46B0.7%$33.93B
ILMN$4.54B+5.8%$895.00M19.7%$33.38B
LH$14.59B+6.0%$1.00B6.9%$30.19B

CDNA FAQ

7 questions
  • What is CDNA revenue?
    CareDx Inc. (CDNA) reported $497.40M of revenue for the twelve months ended Sep 30, 2026. That is up 38.9% from the year before. Revenue for fiscal 2025 was $379.81M.
  • Is CDNA profitable?
    Yes. CareDx Inc. earned $128.63M in net income for the twelve months ended Sep 30, 2026, a net margin of 25.9%.
  • How much cash and debt does CDNA have?
    CareDx Inc. reported $250.48M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is CDNA revenue growing?
    CareDx Inc.'s revenue changed +13.8% in fiscal 2025, to $379.81M. Its compound annual growth rate was +14.6% over 5 years and +29.7% over 10 years.
  • What is CDNA earnings per share?
    Diluted earnings per share were $2.39 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did CDNA last report financial results?
    The latest statements here come from CareDx Inc.'s 10-Q filed on Oct 29, 2026, covering the period ended Sep 30, 2026.
  • Where does this CDNA financial data come from?
    Quantisnow builds these statements from the structured XBRL data CareDx Inc. files with the SEC. It is provided for information only and is not investment advice.